Anti-L1CAM antibodies and uses thereof
AssigneeApitBio, Inc
InventorsHyo Jeong Hong, Heesu Chae, Jisu Hong
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies that specifically bind to L1CAM and compositions comprising such antibodies. Also provided herein are methods for preventing or treating diseases or conditions which comprise a tumor using the anti-L1CAM antibodies.
Claims20
An isolated antibody or antigen-binding fragment thereof that specifically binds to L1 Cell Adhesion Molecule (L1CAM), wherein
- the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) complementarity determining region 1 (CDR1), CDR2, and CDR3 and a light chain variable region (VL) CDR1, CDR2, and CDR3;
- (i) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO:
- 2), FISNEGSNKYYADSVKG (SEQ ID NO:
- 10), and GRAYGSGSLFDP (SEQ ID NO:
- 4), respectively;
- and
- wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO:
- 12), AASNLHS (SEQ ID NO:
- 7), and QQSIGRGPVT (SEQ ID NO:
- 13), respectively;
- (ii) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO:
- 2), FISNEGSNKYYADSVKG (SEQ ID NO:
- 10), and GRAYGSGSLFDP (SEQ ID NO:
- 4), respectively;
- and
- wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO:
- 12), AASNLHS (SEQ ID NO:
- 7), and QQAGFYSPWT (SEQ ID NO:
- 17), respectively;
- (iii) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO:
- 2), FISNEGSNKYYADSVKG (SEQ ID NO:
- 10), and GRAYGSGSLFDP (SEQ ID NO:
- 4), respectively;
- and
- wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO:
- 12), AASNLHS (SEQ ID NO:
- 7), and QQAGFYTPWT (SEQ ID NO:
- 15), respectively;
- (iv) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO:
- 2), FISNEGSNKYYADSVKG (SEQ ID NO:
- 10), and GRAYGSGSLFDP (SEQ ID NO:
- 4), respectively;
- and
- wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO:
- 12), AASNLHS (SEQ ID NO:
- 7), and QQSLHFYPWT (SEQ ID NO:
- 19), respectively;
- or
- (v) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO:
- 2), FISNEGSNKYYADSVKG (SEQ ID NO:
- 10), and GRAYGSGSLFDP (SEQ ID NO:
- 4), respectively;
- and
- wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO:
- 12), AASNLHS (SEQ ID NO:
- 7), and QQSLVWYPWT (SEQ ID NO:
- 21), respectively.
An antibody or antigen-binding fragment thereof specifically binding to L1CAM, wherein the antibody or antigen-binding fragment thereof comprises a VH and a VL, wherein the VH of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:
- 23 and the VL of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:
- 24.
Dependencies are inferred from the claim text.